Company upsizes loan commitments by CAD $15 million and extends maturities one year to February 2029 Incremental debt capital provides flexibility for additional growth investments at rates below 6.0% VANCOUVER, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF), today announced that on February 20, 2026 it amended and extended its Canadian cannabis credit facility by upsizing loan commitments with existing lenders by CAD $1 ...

Investor Presentation December 31, 2025 CAUTIONARY STATEMENT This document is current as of December 31, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied ...

Core Insights - Aurora Cannabis Inc. reported a net revenue increase of C$7 million to C$94.2 million for the quarter, driven by the global medical cannabis and plant propagation segments [2] - The company is focusing on the higher-margin medical cannabis business, with revenue from this segment rising 12% to C$76.2 million, representing 81% of total revenue [2][4] - Adjusted gross margin improved to 62%, while adjusted EBITDA decreased by 5% year over year to C$18.5 million due to higher operating expenses [3] Financial Performance - The medical cannabis segment's growth was led by a 17% increase in international markets, particularly in Germany and Poland [2] - Management confirmed full year 2026 adjusted EBITDA guidance of C$52–57 million, despite a cautious outlook for the fourth quarter [3] - ACB's balance sheet is strong, with C$154 million in cash and no debt, and the company has filed for an at-the-market offering of up to C$100 million for additional capital flexibility [4] Strategic Focus - ACB is divesting from the less-profitable plant propagation business and exiting select Canadian consumer cannabis markets to focus on international medical opportunities [4] - Management anticipates fiscal year 2026 to be a record revenue year, with continued growth and margin expansion expected through fiscal year 2028 [5] - Despite top-line growth and improved margins, ACB's valuation remains discounted compared to peers and its historical performance, indicating potential for a rerating in 2026 [5]

Core Insights - Aurora Cannabis reported a consolidated adjusted gross margin of 62%, an increase of 100 basis points year over year, with adjusted gross profit rising 6% to CAD 55.6 million [1] - The company’s total net revenue reached CAD 94.2 million, with medical cannabis contributing 81% of this revenue, up from 77% the previous year [2] - CEO Miguel Martin highlighted a 7% year-over-year increase in net revenue, driven by a 12% rise in medical cannabis revenue to CAD 76.2 million, including a 17% growth in international markets [3][4] Financial Performance - For fiscal Q3 2026, net revenue increased 7% year over year to CAD 94.2 million, with adjusted EBITDA at CAD 18.5 million, down from CAD 19.4 million in the prior year [7] - The company generated positive free cash flow of CAD 15.5 million, a decrease from CAD 27.4 million in the previous year, ending the quarter with CAD 154 million in cash and no cannabis-related debt [8] - Adjusted net income was CAD 7.2 million compared to CAD 7.4 million a year earlier [7] Strategic Initiatives - Aurora is exiting select low-margin Canadian consumer markets and plans to divest its controlling stake in Bevo, a plant propagation business, to focus on higher-margin global medical cannabis [6][9] - The company filed a prospectus supplement for a new at-the-market (ATM) equity program to raise up to $100 million for strategic purposes, including increased cultivation capacity and potential M&A [14] - Management anticipates one-time costs in Q4 due to these strategic changes but expects improved adjusted SG&A and margins thereafter [10] Market Expansion - Aurora projects FY2026 global medical cannabis revenue between CAD 269 million and CAD 281 million, representing a growth of 10% to 15% [5][20] - The company is focusing on expanding its presence in Germany, which is described as Europe's largest medical cannabis market, and is doubling production at its German manufacturing site [15][16] - In Poland, Aurora gained market share and held the number one position in 2025, successfully navigating regulatory shifts [18] Future Outlook - Management expects annual consolidated adjusted EBITDA to rise to a range of CAD 52 million to CAD 57 million, indicating 5% to 10% annual growth [21] - The company aims to leverage its regulatory capabilities and manufacturing efficiencies to capitalize on the evolving global medical cannabis market [22]

Financial Data and Key Metrics Changes - Net revenue increased by 7% to CAD 94.2 million, driven by a record 12% growth in global medical cannabis revenue, including a 17% increase internationally [4][16] - Adjusted gross margin rose by 100 basis points to 62%, with adjusted gross profit reaching CAD 55.6 million, a 6% increase [16] - Adjusted EBITDA was CAD 18.5 million, and adjusted net income was CAD 7.2 million, with positive free cash flow of CAD 15.5 million [5][17] - The company ended the quarter with CAD 154 million in cash and no cannabis business-related debt [5][17] Business Line Data and Key Metrics Changes - Medical cannabis net revenue rose by 12% to CAD 76.2 million, comprising 81% of total net revenue, compared to 77% in the prior year [17] - Consumer cannabis net revenue decreased by 48% to CAD 5.2 million, reflecting the strategic shift to focus on higher-margin global medical cannabis [18] - Bevo's plant propagation net revenue increased by 27% to CAD 11.3 million, but adjusted gross margin fell to 16% from 40% due to increased costs [19] Market Data and Key Metrics Changes - The German market, as the largest individual medical cannabis market in Europe, was a primary driver of double-digit growth in international revenue [8][9] - Australia is the largest international medical cannabis market for the company, with a potential AUD 1 billion opportunity, where the company holds the number two market share [11] - In Poland, the company maintained its number one position in market share, benefiting from increased annual import limits [13] Company Strategy and Development Direction - The company is focusing on exiting select markets within the lower Canadian consumer cannabis segment to prioritize higher-margin global medical cannabis [7] - A divestiture of the lower-margin plant propagation operations is planned to allocate capital more effectively and improve profitability [7] - The company aims to enhance its leadership position in global medical cannabis by solidifying its market presence in Canada, Europe, Australia, and New Zealand, while exploring new markets [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive position in the global medical cannabis market, projecting significant growth opportunities [4][23] - The company anticipates annual global medical cannabis net revenue to increase to between CAD 269 million and CAD 281 million, driven by 10%-15% growth in the segment [21][22] - Management acknowledged potential headwinds in some markets but remains optimistic about the overall growth trajectory [55] Other Important Information - The company filed a prospectus supplement to establish a new At-the-Market equity program, allowing it to issue and sell up to $100 million of common shares [8] - The company is committed to maintaining high-quality standards in its products, with 90% of annual manufacturing capacity produced in GMP-certified facilities [6] Q&A Session Summary Question: Follow-up on the select market exit in Canada - Management indicated that exiting these markets will be beneficial to overall financial results and will allow for resource reallocation to international markets [25][27] Question: Impact of premiumization strategy in Australia - Management stated that the shift towards premium products is not disruptive and is expected to enhance margins [29][30] Question: Strategic decision to exit plant propagation - Management emphasized the focus on global medical cannabis as the most profitable area and the rationale behind divesting the plant propagation business [37][39] Question: Contribution of plant propagation to EBITDA - Management noted that the financial results of the plant propagation business will be treated as discontinued operations going forward [40] Question: Navigating regulatory changes in Poland - Management highlighted the company's strong relationships with regulators and its ability to adapt to changes in the regulatory environment [42][43] Question: Clarity on global medical cannabis revenue guidance - Management clarified that the guidance reflects total revenue, including the impact of the divestiture of Bevo [48][49] Question: Reasons for higher wholesale gross margins compared to consumer cannabis - Management explained that the consumer cannabis market is tight, leading to lower margins, while wholesale products are less available globally due to regulatory requirements [56][57] Question: Potential assets for M&A - Management expressed interest in cultivation capacity and other aspects of global medical cannabis, remaining opportunistic with the funds raised [61][62] Question: Supply chain and cultivation capacity - Management confirmed that nearly all products sold are produced in-house, with a focus on maintaining high-quality GMP flower [75][78]

Core Insights - CC Pharma, the European pharmaceutical distribution business of Tilray Brands, has been recognized as a TOP 100 Innovator in Germany, highlighting its innovative strength and contributions to the pharmaceutical sector [1][3]. Company Overview - CC Pharma operates a nationwide distribution network serving over 13,000 pharmacies in Germany, providing access to a wide range of prescription and over-the-counter medicines [2]. - The company is also a key player in the distribution of medical cannabis in Germany, utilizing its established infrastructure and regulatory expertise to enhance patient access in a regulated market [2]. Recognition and Awards - The TOP 100 Innovator Award has been recognizing companies for over 25 years based on their innovative management, forward-looking strategies, and sustainable competitiveness [3]. - CC Pharma's selection as a TOP 100 Innovator reflects its disciplined innovation strategy and commitment to operational excellence in a highly regulated market [4]. Leadership Statements - Rajnish Ohri, President of International at Tilray Brands, emphasized that this recognition underscores CC Pharma's role as a reliable partner in Germany's pharmaceutical ecosystem, focusing on building resilient systems and delivering value [4]. - Mathias Bossen, Managing Director of CC Pharma, expressed pride in the award, highlighting the team's focus on continuous improvement and digitalization, positioning the company as a trusted partner in the pharmaceutical value chain [4]. Market Position - CC Pharma's recognition as a TOP 100 Innovator enhances its reputation as an attractive employer and a significant contributor to Germany's healthcare supply chain [4].

Core Viewpoint - Aurora Cannabis Inc. has announced the establishment of a new at-the-market offering program allowing the issuance and sale of up to U.S.$100 million of common shares to the public at the company's discretion [1]. Group 1: Offering Details - The net proceeds from the offering will be used for strategic and accretive purposes, including increased cultivation capacity and mergers and acquisitions (M&A) [2]. - Common shares will be sold through "at-the-market distributions" on the NASDAQ or other U.S. marketplaces at the prevailing market price, with no sales occurring in Canada [3]. - The sales will be conducted under a sales agreement with TD Securities (USA) LLC dated February 4, 2026 [4]. Group 2: Regulatory Filings - A prospectus supplement has been filed with securities commissions in Canada (excluding Quebec) and with the U.S. Securities and Exchange Commission (SEC) as part of the company's registration statement under the U.S./Canada Multijurisdictional Disclosure System [5]. Group 3: Company Overview - Aurora Cannabis is a global leader in medical cannabis, focusing on improving lives through scientific expertise and a commitment to patient care, serving both medical and consumer markets across multiple regions [7]. - The company has a portfolio of trusted brands and holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants [7].

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025. 11 1 "Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market. We achieved record quarterly net revenue of $76.2 million in our globa ...

Core Insights - CC Pharma has been recognized as a TOP 100 Innovator in Germany, highlighting its innovative strength and role as a trusted partner in the European pharmaceutical market [1][3][4] Company Overview - CC Pharma operates a nationwide pharmaceutical distribution network serving over 13,000 pharmacies in Germany, providing access to a wide range of prescription and over-the-counter medicines [2] - The company is also a key player in the distribution of medical cannabis in Germany, utilizing its established infrastructure and regulatory expertise to enhance patient access [2][4] Award Significance - The TOP 100 Innovator Award has been recognizing companies for over 25 years based on their innovative management, forward-looking strategies, and sustainable competitiveness [3] - This award serves as a trusted signal to various stakeholders, including customers, suppliers, and financial institutions, affirming the company's market position [3] Leadership Statements - Rajnish Ohri, President of International at Tilray Brands, emphasized that the recognition reflects CC Pharma's commitment to innovation and its role in the pharmaceutical ecosystem [4] - Mathias Bossen, Managing Director of CC Pharma, stated that the award validates the team's efforts in continuous improvement and positions the company as a reliable partner in the pharmaceutical value chain [4] Operational Excellence - CC Pharma's selection as a TOP 100 Innovator underscores its disciplined innovation strategy and commitment to operational excellence in a highly regulated market [4] - The award also highlights CC Pharma's attractiveness as an employer and its significant contribution to Germany's healthcare supply chain [4]

Group 1: Market Overview - Cannabis stocks to watch include Tilray Brands, Canopy Growth, Aurora Cannabis, Silver Spike Investment, and Cronos Group, identified by MarketBeat's stock screener tool [2] - Cannabis stocks are characterized by higher regulatory and legal risks, and they tend to be more volatile than the broader market due to changing laws and consumer demand [2] Group 2: Company Profiles - **Tilray Brands (TLRY)**: Engages in research, cultivation, processing, and distribution of medical cannabis, operating in multiple countries including Canada, Australia, and Germany [3] - **Canopy Growth (CGC)**: Involved in the production, distribution, and sale of cannabis and hemp-based products, primarily in the U.S., Canada, and Germany, with operations segmented into Canada Cannabis and International Markets Cannabis [3] - **Aurora Cannabis (ACB)**: Produces and sells cannabis products in Canada and internationally, operating through Canadian Cannabis, European Cannabis, and Plant Propagation segments [4] - **Silver Spike Investment (SSIC)**: A specialty finance company that invests in the cannabis ecosystem through direct loans and equity ownership of privately held cannabis companies [4] - **Cronos Group (CRON)**: Engages in the cultivation and marketing of cannabis products in Canada, Israel, and Germany, offering a variety of products under several brands [5]